Risk Management Plan

for

Pregabalin Accord 25 mg /50 mg /75 mg /100 mg /150 mg /200 mg /225 mg/ 300 mg hard capsules

(Pregabalin)

RMP version to be assessed as part of this application:

RMP Version number	6.0
Data lock point for this RMP	08-Aug-2024
Date of final sign off	18-Dec-2024

Rationale for submitting an updated RMP: This RMP has been updated in-line with European Public Assessment (EPAR) – Risk Management Plan of Lyrica (pregabalin), version 14.1, dated 22-Feb-2024.

Summary of significant changes in this RMP: Significant changes have been done in followings sections of RMP: Part IPart-II (Module SVII), Part-III (Module SVIII), Part III (III.1), Part VI (II.A), and Part-VII (Annex 4, Annex 7 & Annex 8).

Other RMP versions under evaluation: Not applicable

Details of the currently approved RMP:

Version number	Approved with procedure:	Date of approval (opinion date):
5.0	EMEA/H/C/004024 - EMA/VR/0000174437	20-May-2024

QPPV Name : Arletta Werynska

QPPV Signature : 

TABLE OF CONTENTS

[redacted]

[redacted].

LIST OF TABLES

Part I: Products Overview

Table 1: Product Overview

Active substance (INN or common name)	Pregabalin
Pharmacotherapeutic group(s) (ATC Code)	**Pharmacotherapeutic group:** Analgesics, other analgesics and antipyretics, Gabapentinoids **ATC Code:** N02BF02
Marketing Authorisation Holder	Accord Healthcare S.L.U., Spain
Medicinal products to which this RMP refers	8
Invented names in the European Economic Area (EEA)	Pregabalin Accord 25 mg hard capsules Pregabalin Accord 50 mg hard capsules Pregabalin Accord 75 mg hard capsules Pregabalin Accord 100 mg hard capsules Pregabalin Accord 150 mg hard capsules Pregabalin Accord 200 mg hard capsules Pregabalin Accord 225 mg hard capsules Pregabalin Accord 300 mg hard capsules
Marketing authorisation procedure	Centralised procedure (EMEA/H/C/004024)
Brief description of the product	***Chemical class:*** Pregabalin is a 3-isobutyl derivative of gamma-aminobutyric acid analogue [(S) -3- (aminomethyl) -5-methylhexanoic acid].
	Summary of mode of action: Pregabalin binds to an auxiliary subunit (α_2-δ protein) of voltage-gated calcium channels in the central nervous system.

[redacted]

	Important information about its composition Each 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg hard capsules contain 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg of pregabalin in their respective formulation.
Hyperlink to the Product Information	Refer Module 1.3.1 for Product Information
Indications	***Current*** Pregabalin Accord is indicated for the following conditions: Neuropathic pain Pregabalin Accord is indicated for the treatment of peripheral and central neuropathic pain in adults. Epilepsy Pregabalin Accord is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. Generalised Anxiety Disorder Pregabalin Accord is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
Dosage	***Current*** Posology: The dose range is 150 to 600 mg per day given in either two or three divided doses. *Neuropathic pain* Pregabalin treatment can be started at a dose of 150 mg per day given as two or three divided doses. Based on individual patient response and tolerability, the dose may be increased to 300 mg per

	day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval. *Epilepsy* Pregabalin treatment can be started with a dose of 150 mg per day given as two or three divided doses. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. The maximum dose of 600 mg per day may be achieved after an additional week. *Generalised Anxiety Disorder* The dose range is 150 to 600 mg per day given as two or three divided doses. The need for treatment should be reassessed regularly. Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. Following an additional week the dose may be increased to 450 mg per day. The maximum dose of 600 mg per day may be achieved after an additional week. Method of administration: Pregabalin may be taken with or without food. Pregabalin is for oral use only.
Pharmaceutical forms and strengths	***Current*** Hard capsules 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg
Is the product subject to additional monitoring in EU?	No

[redacted].

Part II: Safety specification

Module SI – Epidemiology of the indication(s) and target population(s)

Not applicable

Module SII – Non-clinical part of the safety specification

Not applicable

Module SIII – Clinical trial exposure

Not applicable

Module SIV – Populations not studied in clinical trials

SIV.1 Exclusion criteria in pivotal clinical studies within the development programme

Not applicable

SIV.2 Limitations to detect adverse reactions in clinical trial development programmes

Not applicable

SIV.3 Limitations in respect to populations typically under-represented in clinical trial development programmes

Not applicable

Module SV – Post-authorisation experience

SV.1 Post-authorisation exposure

Not applicable

Module SVI – Additional EU requirements for the safety specification

SVI.1 Potential for misuse for illegal purposes

Not applicable

[redacted]

Module SVII – Identified and potential risks

The safety concerns for this Risk Management Plan (RMP) have been updated as per European Public Assessment Report (EPAR) - RMP of Lyrica (pregabalin), version 14.1, dated 22-Feb-2024, published by EMA on 02-Jul-2024. There is no change proposed by MAH in these safety concerns mentioned in Module SVIII which are in-line with summary of safety concerns for reference product.

Hence, this section remains "Not applicable".

SVII.1 Identification of safety concerns in the initial RMP submission

SVII.1.1 Risks not considered important for inclusion in the list of safety concerns in the RMP

Not applicable

SVII.1.2 Risks considered important for inclusion in the list of safety concerns in the RMP

Not applicable

SVII.2 New safety concerns and reclassification with a submission of an updated RMP

Not applicable

SVII.3 Details of important identified risks, important potential risks, and missing information

SVII.3.1 Presentation of important identified risks and important potential risks

Not applicable

SVII.3.2 Presentation of the missing information

Not Applicable

Module SVIII – Summary of the safety concerns

Table 2: Summary of safety concerns

Important identified risks	• Dizziness, somnolence, loss of consciousness, syncope and potential for accidental injury • Discontinuation events • Drug interactions (lorazepam, ethanol and CNS depressants) • Euphoria • Congestive heart failure • Vision-related events
Important potential risks	• Suicidality • Off-label use in paediatric patients
Missing Information	• None

[redacted]

Part III: Pharmacovigilance Plan (including post-authorisation safety studies)

III.1 Routine pharmacovigilance activities

Routine pharmacovigilance activities including collection and reporting of adverse reactions and signal detection as stated in pharmacovigilance system master file are sufficient for the mentioned safety concerns.

III.2 Additional pharmacovigilance activities

None proposed

III.3 Summary Table of additional Pharmacovigilance activities

Not applicable

Part IV: Plans for post-authorisation efficacy studies

Not applicable

Part V: Risk minimisation measures (including evaluation of the effectiveness of risk minimisation activities)

Risk Minimisation Plan

The safety information in the proposed product information is aligned to the reference medicinal product.

V.1 Routine Risk Minimisation Measures

Not Applicable

V.2 Additional Risk Minimisation Measures

None proposed

V.3 Summary of risk minimisation measures

Not Applicable

Part VI: Summary of the risk management plan

Summary of risk management plan for Pregabalin Accord 25mg / 50mg / 75mg / 100mg / 150mg / 200mg / 225mg / 300mg hard capsules (pregabalin)

This is a summary of the risk management plan (RMP) for Pregabalin Accord 25mg / 50mg / 75mg / 100mg / 150mg / 200mg / 225mg and 300mg hard capsules. Throughout this summary the products have been referred to as Pregabalin Accord hard capsules. The RMP details important risks of Pregabalin Accord hard capsules, how these risks can be minimised, and how more information will be obtained about Pregabalin Accord hard capsule's risks and uncertainties (missing information).

Pregabalin Accord hard capsule's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Pregabalin Accord hard capsules should be used.

This summary of the RMP for Pregabalin Accord hard capsules should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Pregabalin Accord hard capsule's RMP.

I. The medicine and what it is used for

Pregabalin Accord hard capsules are indicated for the following conditions:

Neuropathic pain

Pregabalin Accord is indicated for the treatment of peripheral and central neuropathic pain in adults.

Epilepsy

Pregabalin Accord is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Generalised Anxiety Disorder

Pregabalin Accord is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.

It contains pregabalin as the active substance and it is for oral use only.

[redacted]

Further information about the evaluation of Pregabalin Accord hard capsules' benefits can be found in Pregabalin Accord hard capsules' EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-accord.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Pregabalin Accord hard capsules, together with measures to minimise such risks and the proposed studies for learning more about Pregabalin Accord hard capsules' risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks Pregabalin Accord hard capsules are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Pregabalin Accord hard capsules. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation.

[redacted]

Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Important identified risks	• Dizziness, somnolence, loss of consciousness, syncope and potential for accidental injury • Discontinuation events • Drug interactions (lorazepam, ethanol and CNS depressants) • Congestive heart failure • Euphoria • Vision-related events
Important potential risks	• Suicidality • Off-label use in paediatric patients
Missing information	• None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Pregabalin Accord hard capsules.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Pregabalin Accord hard capsules as post-authorisation development plan.